Red Light Therapy for Sinuses & Respiratory

Intranasal red light therapy devices are some of the most commonly marketed consumer PBM products. You can find dozens of clip-on nasal probes on Amazon promising to clear your sinuses, cure your allergies, and help you breathe freely. The question, as always, is what the evidence actually supports.

The answer is genuinely mixed. There is some evidence for certain applications — particularly allergic rhinitis — but many claims are overblown, and the evidence for serious respiratory conditions like asthma and COPD ranges from thin to non-existent.

This page covers sinusitis, rhinitis, allergies, hayfever, and respiratory conditions, separating what has some scientific backing from what is marketing fantasy.

Anatomy and light delivery

Understanding whether PBM can affect the sinuses and respiratory tract requires understanding the anatomy and how light reaches these structures.

The nasal cavity

The nasal cavity is lined with highly vascular mucosa. When an intranasal probe is placed inside the nostril, the light has direct access to this mucosal tissue — no need to penetrate skin, fat, or muscle. This is a significant advantage over, say, trying to treat the gut through the abdominal wall.

Red light (660nm) and near-infrared (810–850nm) can penetrate the thin nasal mucosa and reach underlying blood vessels, nerves, and immune cells. The nasal mucosa is only about 1–3mm thick, so penetration depth is not a limiting factor here.

The paranasal sinuses

The sinuses (maxillary, frontal, ethmoid, sphenoid) are air-filled cavities lined with mucosa, connected to the nasal cavity via small openings (ostia). Light from an intranasal device can reach the inferior turbinate and parts of the middle meatus but has limited direct access to the sinus cavities themselves, which are surrounded by bone.

Some light may pass through thin bone (particularly the ethmoid and parts of the maxillary sinus wall), but the dose would be heavily attenuated. Claims that a nasal clip can “clear your sinuses” should be viewed with this anatomical limitation in mind.

The lower respiratory tract

The trachea, bronchi, and lungs are not accessible to transcutaneous or intranasal light delivery. Any effect of PBM on asthma, COPD, or other lower respiratory conditions would need to occur through systemic mechanisms (immune modulation, circulating mediators) rather than direct tissue irradiation.

Allergic rhinitis (hayfever)

This is the best-studied application of intranasal PBM and has the most supporting evidence.

The condition

Allergic rhinitis affects 10–30% of the global population. In the UK, hayfever affects approximately 13 million people. Symptoms include nasal congestion, sneezing, rhinorrhoea (runny nose), itching, and often concurrent eye symptoms (allergic conjunctivitis).

The underlying mechanism involves IgE-mediated mast cell degranulation in response to allergens (pollen, dust mites, animal dander), releasing histamine and other inflammatory mediators that cause mucosal swelling, mucus production, and nerve stimulation.

The evidence

Neuman and Finkelstein (1997) conducted a double-blind RCT examining intranasal 660nm light in 50 patients with allergic rhinitis. Treatment was delivered 3 times daily for 14 days. The LLLT group showed significant improvement in nasal congestion, sneezing, rhinorrhoea, and itching compared to placebo. Nasal biopsy samples showed reduced eosinophil infiltration (a marker of allergic inflammation) in the treatment group.

Albu and Balanescu (2013) published a randomised study of intranasal 652nm laser therapy in patients with allergic rhinitis. They found significant reduction in symptom scores and improved nasal airflow measurements compared to sham treatment. Effects were maintained at 2-week follow-up.

Koreck et al. (2005) examined intranasal PBM using a combination of 660nm, 880nm, and 950nm in 49 patients with allergic rhinitis. The treatment group showed significant improvement in total nasal symptom scores, including reduced sneezing, nasal itching, and rhinorrhoea. Importantly, they also measured reduced levels of IL-5 (an eosinophil-activating cytokine) and eosinophilic cationic protein in nasal lavage, providing a mechanistic explanation for the clinical improvement.

Cingi et al. (2010) reported positive results with intranasal 660nm therapy for allergic rhinitis, with significant improvement in nasal congestion and overall symptom scores.

Proposed mechanism for allergic rhinitis

The evidence suggests PBM works in allergic rhinitis through:

1. Mast cell stabilisation — Reducing histamine release from mast cells in the nasal mucosa, similar to the effect of cromoglycate (a mast cell stabiliser used in allergy treatment)
2. Eosinophil suppression — Reducing eosinophil recruitment and activation, as demonstrated by biopsy and lavage studies
3. Anti-inflammatory cytokine modulation — Reducing IL-5 and other allergic inflammatory mediators
4. Improved mucosal blood flow — Reduced oedema and congestion through improved venous drainage

Assessment

Allergic rhinitis is the most evidence-based application of intranasal PBM. The studies are not large, but they are methodologically reasonable (blinded, randomised, with objective outcome measures including histological data). This is not a “miracle cure” claim — the effect sizes are comparable to antihistamines or intranasal corticosteroids rather than dramatically superior to them.

Chronic sinusitis

The condition

Chronic rhinosinusitis (CRS) is inflammation of the sinuses lasting more than 12 weeks. It may present with or without nasal polyps. Symptoms include facial pain/pressure, nasal congestion, purulent discharge, and reduced sense of smell. CRS affects approximately 10% of the European population.

The evidence

The evidence for PBM in chronic sinusitis is much weaker than for allergic rhinitis.

Naghdi et al. (2013) examined LLLT as an adjunct to conventional sinusitis treatment. Results showed some improvement in symptoms, but the study was small and not robustly controlled.

Most sinusitis-related PBM research has focused on post-surgical healing (after functional endoscopic sinus surgery, or FESS) rather than treatment of the sinusitis itself. A few studies suggest PBM may improve mucosal healing after FESS, but this is a narrow clinical application.

The fundamental problem is that chronic sinusitis often involves structural issues (ostial obstruction, polyps, septal deviation), bacterial biofilms, and/or immune dysfunction that light therapy cannot address. Intranasal PBM might reduce mucosal inflammation, but it cannot open a blocked sinus ostium, remove polyps, or eradicate a bacterial biofilm.

Assessment

Insufficient evidence to recommend PBM for chronic sinusitis. It may offer modest symptomatic relief through mucosal anti-inflammatory effects, but it is not a substitute for appropriate medical or surgical management.

Acute sinusitis (sinus infections)

The evidence

There is essentially no published clinical evidence for PBM in acute bacterial sinusitis. Acute sinusitis is typically self-limiting (viral) or treated with antibiotics (bacterial). Adding PBM to the treatment of acute sinusitis is untested.

Some consumer devices are marketed for “clearing sinus infections.” There is no evidence supporting this claim.

Asthma

The condition

Asthma is a chronic inflammatory disease of the lower airways, characterised by bronchial hyperresponsiveness, airway inflammation, and reversible airflow obstruction. It affects approximately 5.4 million people in the UK.

The evidence

Human clinical evidence for PBM in asthma is very limited.

Aimbire et al. (2006, 2008) published a series of animal studies showing that LLLT reduced airway inflammation in rat models of asthma. These studies demonstrated reduced inflammatory cell infiltration, decreased TNF-alpha, and improved airway reactivity. The results were consistent and biologically plausible.

However, the translation gap between animal models and human asthma is well documented. Many therapies that work in animal asthma models fail in human trials. No well-designed RCT has demonstrated that PBM improves asthma control, lung function, or exacerbation rates in human patients.

De Lima et al. (2011) examined LLLT in a mouse model of allergic airway inflammation and found reduced eosinophilic inflammation and mucus production. Again, animal-only.

Assessment

The animal evidence is interesting but insufficient to recommend PBM for asthma. Asthma is a serious condition with well-established, effective treatments (inhaled corticosteroids, bronchodilators, biologics). Suggesting PBM as an alternative is unsupported and potentially dangerous if it leads to patients neglecting their prescribed inhalers.

If PBM has any role in asthma, it would be as an adjunct to (never a replacement for) established treatment, and this would need human trial evidence to justify.

COPD (chronic obstructive pulmonary disease)

The evidence

COPD is a progressive, largely irreversible airway disease primarily caused by smoking. The evidence for PBM in COPD is even thinner than for asthma.

De Marchi et al. (2012) examined PBM as an adjunct to pulmonary rehabilitation in COPD patients. They reported improved exercise tolerance and reduced dyspnoea in the PBM group. However, this study was small and the PBM was applied to exercising muscles (quadriceps, chest wall) rather than to the airways directly. The benefit may have been related to enhanced muscle performance rather than any respiratory effect.

Assessment

Insufficient evidence. PBM applied to respiratory muscles during exercise may improve exercise tolerance in COPD patients (consistent with its effects on muscle performance and recovery in general), but there is no evidence it improves the underlying lung disease.

Intranasal PBM devices: a buyer’s guide

Given the moderate evidence for allergic rhinitis and the limited evidence for other conditions, here is a practical assessment of intranasal PBM devices:

What to look for

• Wavelength: 630–660nm (red) has the most evidence for allergic rhinitis
• Power output: 5–20mW per nostril is typical and consistent with research parameters
• Timer: Treatment durations of 10–30 minutes per session
• Safety certification: CE marking (for UK/EU) or equivalent

What to be sceptical of

• Claims of “clearing sinus infections” — Unsupported
• Claims of treating asthma or COPD — Unsupported
• Devices combining red with blue or UV light — Blue light has antimicrobial properties but UV in the nose is a safety concern; ensure no UV is emitted
• Extremely cheap devices — May not deliver stated power output; no way to verify without a power meter

Recommended protocol for allergic rhinitis

Based on the clinical evidence:

• Wavelength: 630–660nm (red)
• Delivery: Intranasal probe, one per nostril
• Duration: 10–20 minutes per session
• Frequency: 2–3 times daily during peak allergy season; daily as maintenance
• Treatment course: Begin 2–4 weeks before expected allergy season for best results
• Dosage: Approximately 2–6 J per nostril per session (depending on device power)

Complementary measures

PBM for allergic rhinitis works best alongside:

• Allergen avoidance strategies
• Nasal saline irrigation
• Antihistamines (PBM does not replace these for moderate-severe symptoms)
• Intranasal corticosteroids for persistent symptoms
• Consultation with an allergist for severe or treatment-resistant allergic rhinitis

Common claims debunked

”Red light therapy clears your sinuses instantly”

No. Even in the positive allergic rhinitis studies, symptom improvement developed over days to weeks of regular treatment. There is no instant decongestant effect.

”Intranasal red light kills bacteria and viruses”

Red light (630–660nm) is not antimicrobial at the doses used in consumer devices. Antimicrobial photodynamic therapy requires specific photosensitisers and higher energy doses, typically delivered in clinical settings. Your nasal probe is not killing pathogens.

”Red light therapy cures asthma”

No clinical evidence supports this claim. Animal studies show anti-inflammatory effects in asthma models, but no human trial has demonstrated clinical benefit for asthma.

”Red light therapy is better than antihistamines”

The allergic rhinitis studies show PBM achieving comparable (not superior) symptom improvement to antihistamines. For most patients, antihistamines are cheaper, more convenient, and better studied. PBM may be a useful adjunct or alternative for patients who prefer non-pharmacological approaches or experience antihistamine side effects (drowsiness, dry mouth).

The bottom line

Intranasal PBM for allergic rhinitis has genuine, if modest, evidence from multiple small RCTs. It appears to reduce nasal allergy symptoms through mast cell stabilisation and eosinophil suppression. For hayfever sufferers looking for a non-pharmacological option, it is worth trying.

For everything else — chronic sinusitis, acute sinus infections, asthma, COPD — the evidence is inadequate to make recommendations. PBM may offer marginal symptomatic benefit through general anti-inflammatory effects, but it is not a treatment for these conditions.

If you have asthma or COPD, use your prescribed inhalers. If you have chronic sinusitis, see an ENT specialist. If you have seasonal allergies and want to try something alongside your antihistamines, an intranasal red light device is a reasonable experiment with a plausible scientific basis — just keep your expectations measured.